Table 1

Demographics of adult CF lung transplant recipients and HEV serostatus

HEV seropositive (n=6), N (%)HEV seronegative (n=23), N (%)
Characteristic
 Female sex2 (33)13 (57)
 Median age, years (IQR)40.4 (34.1–47.3)37.6 (29.3–49.5)
 Rural postal code1 (17)5 (22)
CF-related factors
 Genotype
  ΔF508 homozygous4 (67)14 (61)
  ΔF508 heterozygous2 (33)8 (35)
 Other01 (4)
 CF comorbidities
  Pancreatic insufficiency6 (100)20 (87)
  CF liver disease3 (50)7 (30)
  GORD3 (50)16 (70)
  Distal intestinal obstruction syndrome6 (100)21 (91)
  CF arthropathy1 (17)2 (9)
  Sinus disease (polyps or nasal congestion)6 (100)19 (83)
Pretransplant factors
 Median age at time of transplant, years (IQR)28.6 (22.1–32.5)31.3 (25.6–36.1)
 Median BMI at time of transplant (IQR, kg/m2)20.9 (18.7–22.1)19.9 (18.4–21.9)
 Per cent predicted forced expiratory volume predicted at time of transplant, median (IQR)22.7 (15.1–28.3)23.5 (16.0–31.8)
 CF-related diabetes (pretransplant prevalence)3 (50)11 (48)
 Chronic Pseudomonas aeruginosa infection6 (100)21 (91)
Post-transplant factors
 CF-related diabetes (post-transplant prevalence)4 (67)15 (66)
 Blood product received at time of transplant6 (100)20 (87)*
 CMV status
  Donor+, recipient−2 (33)7 (30)
  Donor+, recipient+4 (67)15 (66)
 Other01 (4)
 Maintenance immunosuppression†
  Tacrolimus6 (100)22 (96)
  Corticosteroids6 (100)23 (100)
  Mycophenolate5 (83)20 (87)
  Azathioprine1 (17)3 (13)
  Sirolimus01 (4)
 Patients with ≥1 acute cellular rejection episode2 (33)9 (29)
  • *Reported for those with available records at time of transplantation. Two individuals in the seronegative group did not have records available.

  • †Patients were often on multiple drug regimens and thus numbers greater than total sum of patients. Immunosuppressive regimen at time of HEV serostatus determination is reported.

  • BMI, body mass index; CF, cystic fibrosis; CMV, cytomegalovirus; HEV, hepatitis E virus.